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five-year disease-specific survival for the entire cohort was 34%, 
with a median follow-up of 39 months for survivors. Thirty-four 
(74%) of 46 patients relapsed, with a median relapse-free survival 
of 10 months and an overall recurrence rate of 53% at 1 year. The 
majority of patients developed distant recurrences. No differences 
were seen in patterns of relapse between patients treated with an 
APR or a LE: 5 of 19 (26%) patients in the APR group and 7 of 27 
(26%) in the LE group developed local recurrence as the first site 
of relapse. Survival was similar in both groups, with 5-year dis-
ease-specific survivals of 32% for the APR group and 35% for the 
LE group. These findings suggest that local recurrence and sur-
vival in patients with an anorectal melanoma are not associated 
with the extent of resection.
A systematic review that included 14 series also showed no stage-
specific survival advantage for the APR [2]. Recently Nilsson and 
Ragnarsson-Olding [3] reported that there was no statistically sig-
nificant difference in terms of median survival (11 months vs. 14 
months) or the five-year survival rate (7% vs. 15%) between pa-
tients treated with the APR or the LE (P = 0.084). When 72 pa-
tients in whom a R0 resection had been achieved were compared 
with patients having involved margins (R+), there was a signifi-
cant difference in survival in favor of the R0 resection; thus, both 
the APR and the LE seemed appropriate for treating an anorectal 
melanoma, provided clear margins could be achieved. Because of 
the APR having no survival advantage over the LE and because of 
the poor prognosis associated with an anorectal melanoma, fur-
ther consideration must be given to quality-of-life issues when 
making treatment decisions between these two treatment options.
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An anorectal melanoma is a rare tumor with poor survival. The 
clinical diagnosis of an anorectal melanoma is difficult because of 
its nonspecific symptoms and the lack of pigmentation in a signif-
icant proportion of lesions (37% in this report). To my knowledge, 
this is the largest clinical series studying anorectal melanomas in 
Korea even though the number of cases (19 cases) is small.
Although the majority of patients die of systemic metastasis, the 
role of adjuvant chemotherapy and immunotherapy in the treat-
ment of an anorectal melanoma is minimal. The major debate is 
the extent of surgery (wide local excision versus radical resection). 
Within the limitation of a small number of cases and a short fol-
low up, this study suggests that the abdominoperineal resection 
(APR) may provide a longer survival, compared with the wide lo-
cal excision, in cases involving an anorectal melanoma. 
In a retrospective study at the Memorial Sloan-Kettering Cancer 
Center, Yeh et al. [1] reported a change in practice patterns during 
20 years. In their study of 46 patients with an anorectal melanoma, 
the authors noted a paradigm shift in the treatment strategy from 
APR to local excision (LE). They reported that, between 1984 and 
1996, 15 of 21 (71%) patients treated for primary an anorectal mel-
anoma underwent an APR. From 1997 to 2003, however, 21 of 25 
(84%) patients treated for an anorectal melanoma underwent a 
LE. During these respective periods, no changes were seen in the 
thicknesses and the diameters of the tumors. In addition, the pat-
tern of relapse, the time to relapse, and the disease-specific mortal-
ity remained similar in these two cohorts. Despite the clear change 
in practice patterns during these two periods, the outcomes were 
not significantly different, regardless of the extent of resection. The 
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